News

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

September 4, 2019

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, as Chief Medical Officer (CMO). In his new role, and as a prominent expert and accomplished clinician, Dr. Den will lea...

June 18, 2019

We're excited that at this year’s American Brachytherapy Society (ABS) Meeting, Prof. Keisari was awarded the Best Oral Presentation Award at the Breast Plenary Session!

Prof. Keisari presented his results on “Immunomodulation of the Antitumor Response Induced by Alpha...

April 11, 2019

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016 certification. The certification was awarded following an audit by the UK's independent national compliance body, British St...

March 26, 2019

Tel Aviv, Israel, March 26, 2019 – Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that Mr. Raphi Levy will be joining Alpha Tau’s management team as Chief Financial Officer. Mr. Levy will focus primarily on...

December 20, 2018

Alpha Tau Medical today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the JP Morgan Healthcare week at the Hilton San Francisco Union Square.

Alpha TAU's CEO, Uzi Sofer, will present as follows:

Date: Tuesday, January...

November 7, 2018

Trials will investigate the efficacy of its breakthrough cancer treatment, Alpha DaRT, in Squamous Cell Carcinoma (SCC) of the Skin, and Cutaneous and Mucosal malignant Neoplasia (CMN)

TEL AVIV, Israel--(BUSINESS WIRE)--Alpha Tau Medical, developer of a breakthrough alp...

September 5, 2018

Proceeds to accelerate expansion of global clinical research program and establish new production facilities to meet growing demand for the company's breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).

TEL AVIV, Israel, -- Alpha Tau M...

August 22, 2018

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy).  

Boston, MA, August 21st 2018 --...

August 22, 2018

[..] Another company from Tel Aviv, Alpha Tau Medical, has partnered with Japanese biotechnology startup HekaBio to release radiation therapy equipment in Japan in 2021, at the earliest.

The product is designed to treat patients with breast, skin and other solid cancers...

Please reload

Categories
Please reload

Sign up
Featured Posts